BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29153885)

  • 1. Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions.
    Gandaglia G; Tilki D; Zaffuto E; Fossati N; Pompe RS; Dell'Oglio P; Graefen M; Montorsi F; Briganti A
    Eur Urol Focus; 2019 Jul; 5(4):545-549. PubMed ID: 29153885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
    Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
    Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer.
    Dell'Oglio P; Karnes RJ; Joniau S; Spahn M; Gontero P; Tosco L; Fossati N; Kneitz B; Chlosta P; Graefen M; Marchioro G; Bianchi M; Sanchez-Salas R; Karakiewicz PI; Poppel HV; Montorsi F; Briganti A;
    Urol Oncol; 2016 May; 34(5):234.e13-9. PubMed ID: 26706120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses.
    Koo KC; Cho JS; Bang WJ; Lee SH; Cho SY; Kim SI; Kim SJ; Rha KH; Hong SJ; Chung BH
    Cancer Res Treat; 2018 Jan; 50(1):129-137. PubMed ID: 28279064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment?
    Huland H; Graefen M
    Eur Urol; 2015 Aug; 68(2):175-8. PubMed ID: 25736732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients.
    Moltzahn F; Karnes J; Gontero P; Kneitz B; Tombal B; Bader P; Briganti A; Montorsi F; Van Poppel H; Joniau S; Spahn M
    Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):31-7. PubMed ID: 25535100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Gandaglia G; Boorjian SA; Parker WP; Zaffuto E; Fossati N; Bandini M; Dell'Oglio P; Suardi N; Montorsi F; Karnes RJ; Briganti A
    Eur Urol; 2017 Dec; 72(6):910-917. PubMed ID: 28622831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    Johnston TJ; Shaw GL; Lamb AD; Parashar D; Greenberg D; Xiong T; Edwards AL; Gnanapragasam V; Holding P; Herbert P; Davis M; Mizielinsk E; Lane JA; Oxley J; Robinson M; Mason M; Staffurth J; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Prescott S; Paul A; Powell P; Rosario D; Rowe E; Donovan JL; Hamdy FC; Neal DE;
    Eur Urol; 2017 Mar; 71(3):381-388. PubMed ID: 27720537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer.
    Preisser F; Marchioni M; Nazzani S; Bandini M; Tian Z; Saad F; Pompe RS; Briganti A; Budäus L; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
    Eur Urol Oncol; 2018 Jun; 1(2):160-168. PubMed ID: 31100241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
    Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients.
    Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Fossati N; Gandaglia G; Gallina A; Abdollah F; Shariat SF; Montorsi F; Saad F; Tilki D; Briganti A; Karakiewicz PI
    Eur Urol Focus; 2019 May; 5(3):381-388. PubMed ID: 29366856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer.
    Bandini M; Marchioni M; Preisser F; Zaffuto E; Tian Z; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    World J Urol; 2018 Sep; 36(9):1399-1407. PubMed ID: 29717358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up.
    Gandaglia G; Fossati N; Stabile A; Bandini M; Rigatti P; Montorsi F; Briganti A
    Eur Urol; 2017 Aug; 72(2):289-292. PubMed ID: 27574820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is radiotherapy after radical prostatectomy associated with higher other-cause mortality?
    Özman O; Droghetti M; Pos F; van Leeuwen PJ; van der Poel H
    Cancer Causes Control; 2023 Dec; 34(12):1139-1144. PubMed ID: 37522983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation therapy after radical prostatectomy is associated with higher other-cause mortality.
    Würnschimmel C; Wenzel M; Chierigo F; Flammia RS; Horlemann B; Tian Z; Saad F; Briganti A; Shariat SF; Gallucci M; Suardi N; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
    Cancer Causes Control; 2022 May; 33(5):769-777. PubMed ID: 35230576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
    Seiler D; Randazzo M; Klotz L; Grobholz R; Baumgartner M; Isbarn H; Recker F; Kwiatkowski M
    BJU Int; 2012 Jul; 110(2):195-200. PubMed ID: 22093744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncologic outcomes at 10 years following robotic radical prostatectomy.
    Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
    Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.